Development and evaluation of mucoadhesive bigel containing tenofovir and maraviroc for HIV prophylaxis.

Margaret Okonawan IlomuanyaAyotunde T HameedatEdidiong N AkangSabdat O EkamaBoladale O SilvaAlani S Akanmu

Published in: Future journal of pharmaceutical sciences (2020)

This study successfully developed a dual compartment bigel containing maraviroc and tenofovir. BG C was found to be stable and safe towards vaginal and rectal epithelium, and it actively prevented HIV transmission. This bigel has the potential for long-term pre-exposure prophylaxis prevention of HIV transmission.

Keyphrases

antiretroviral therapy
hiv positive
hiv infected
human immunodeficiency virus
hiv testing
hiv aids
hepatitis c virus
men who have sex with men
south africa
rectal cancer